Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Gene therapy company licenses gene from university
June 13th, 2005
Neurologix, Inc., (NRGX) announced that it has licensed the humanin gene from Keio University in Tokyo Japan as part of a strategic move to broaden its product portfolio. The license agreement provides Neurologix with exclusive worldwide rights (excluding Japan) to develop and commercialize therapeutics to treat brain and other central nervous system (CNS) disorders (excluding Amyotrophic Lateral Sclerosis) using the humanin gene. The humanin gene will be used in combination with Neurologix's proprietary gene transfer technology. The resulting therapeutic is expected to be the company's lead compound for a novel and promising approach to Alzheimer...
Source: Health & Medicine Week (2005-06-13)
|
